HBsAg Related Response Guided Therapy

Gangnam Severance Hospital200 enrolled

Overview

Primary objective: Compare Pegasys RGT overall response rate (i.e., HBeAg seroconversion rate) with Pegasys mono historical response rate at week 72 (48 week treatment with 24 week follow up) Secondary objective : * The changes of HBsAg titer * The rate of combined HBeAg seroconversion and HBV DNA \< 300 copies/mL * The rate of serum HBV DNA \< 300 copies/mL ⅳ. The rate of ALT normalization * The rate of HBsAg loss ⅵ. The rate of serum HBV DNA \< 10,000 copies/mL

After 12w treatment of Pegasys, depends on results of quantitative HBsAg test, Patients will be allocated to one of three groups. * HBsAg \>20,000 : study termination * Group A :1,500\<HBsAg≤ 20,000 * Group B : .HBsAg ≤ 1500 At week 48, according to HbeAg seroconversion, patients will be allocated to one of two sub-groups(A-1, A-2, B-1, B-2) Patients are seen for evaluation at treatment weeks 4,8,12,24,36,48. Post-treatment assessments will be performed at 4,12 and 24 week during off-treatment phase for the assessment of the primary and main secondary endpoints of the study.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

200

Conditions

Hepatitis B, Chronic

Interventions

Peginterferon alfa-2aDRUG

Duration and combination

EntecavirDRUG

combination

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Age ≥ 18 years 2. Positive HBsAg for more than 6 months, positive HBeAg, detectable HBV DNA(patients must have \> 100,000 copies/ml as measured by PCR) and anti-HBs negative 3. Elevated serum ALT \> 2ULN but ≤ 10 × ULN as determined by two abnormal values taken ≥ 14 days apart during the six months before the first dose of study drug with at least one of the determinations obtained ≤ 35 days prior to the first dose. Exclusion Criteria: 1. Patients must not have received antiviral therapy for their chronic hepatitis B. Patients who are expected to need systemic antiviral therapy other than that provided by the study at any time during their participation in the study are also excluded. Exception: patients who have had less than 6 months treatment of NA(Nucleos(t)ide analog) and more than 1 year wash-out period for systemic antiviral therapy and negative results in the NA resistance test at baseline are not excluded. 2. Positive test at screening for HAV IgM Ab, HCV-RNA or HCV Ab, HDV Ab or HIV Ab. 3. Diagnosed hepatic cellular carcinoma 4. Any evidence of decompensated liver disease (Childs B-C)

Locations (1)

Shinchon Severance Hospital

Seoul, Seoul, South Korea

RECRUITING

Outcomes

Primary Outcomes

HBeAg seroconversion

Time frame: 24 weeks post treatment follow up

Secondary Outcomes

The changes of HBsAg titer

Time frame: baseline and 24weeks post treatment follow up

Central Contacts

Kwansik Lee, professor

CONTACT

+82 11 9636 9935 leeks519@yuhs.ac

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.